Price Alert

Anebulo Pharmaceuticals I... (ANEB)

NASDAQ: ANEB · Real-Time Price · USD

2.52

-0.20 (-7.35%)

At close: Oct 16, 2025, 3:59 PM

2.53

0.40%

After-hours: Oct 16, 2025, 06:27 PM EDT

-7.35% (1D)

Bid	2.5
Market Cap	103.53M
Revenue (ttm)	n/a
Net Income (ttm)	-7.69M
EPS (ttm)	-0.25
PE Ratio (ttm)	-10.08
Forward PE	-5.12
Analyst	Hold
Dividends	n/a

Ask	2.7
Volume	23,274
Avg. Volume (20D)	426,648
Open	2.62
Previous Close	2.72
Day's Range	2.52 - 2.74
52-Week Range	0.80 - 3.42
Beta	-0.89
Ex-Dividend Date	n/a

About ANEB

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ANEB

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ANEB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

+17.91%

Anebulo Pharmaceuticals shares are trading higher ... Unlock content with Pro Subscription

2 months ago

+81.97%

Anebulo Pharmaceuticals shares are trading higher after the company announced a reverse stock split with a ratio of at least 1-for-2500.

News

2 weeks ago · businesswire.com

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates.

3 weeks ago · businesswire.com

Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced ...

2 months ago · businesswire.com

Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic ...